Market Place
Sourcing Support
Firm Glass Lewis Endorses Aptose Plan of Arrangement
23 Mar 2026 //
GLOBENEWSWIRE
ISS Recommends Approval Of Aptose-Hanmi Pharma Arrangement
19 Mar 2026 //
GLOBENEWSWIRE
Aptose Biosciences Reschedules Hanmi Acquisition Meeting
19 Dec 2025 //
GLOBENEWSWIRE
Hanmi Pharma To Acquire Aptose Biosciences In Arrangement Deal
19 Nov 2025 //
GLOBENEWSWIRE
Aptose Biosciences Reveals Shareholders Meeting Results
22 Aug 2025 //
GLOBENEWSWIRE
Aptose`s Tuspetinib boosts AML treatment in Phase 1/2 Trial
19 Aug 2025 //
GLOBENEWSWIRE
Aptose Reveals Q2 2025 Results
13 Aug 2025 //
GLOBENEWSWIRE
Aptose Picks Ernst & Young Global Limited as New Auditor
01 Aug 2025 //
GLOBENEWSWIRE
Aptose Gets 2nd Loan from Hanmi for Tuspetinib in AML Therapy
15 Jul 2025 //
GLOBENEWSWIRE
Aptose Announces Deferral of Interest Payment
30 Jun 2025 //
GLOBENEWSWIRE
Aptose Provides Corporate Updates
17 Jun 2025 //
GLOBENEWSWIRE
Aptose Presents Safety, Response, & Mrd Data at 2025 EHA Congress
12 Jun 2025 //
GLOBENEWSWIRE
Aptose Announces Results of Shareholder Meeting
27 May 2025 //
GLOBENEWSWIRE
Aptose doses first patient with 120mg Tuspetinib in Tuscany Trial
20 May 2025 //
GLOBENEWSWIRE
Aptose to Present Tuspetinib Data at 2025 EHA Congress
14 May 2025 //
GLOBENEWSWIRE
Aptose Reports First Quarter 2025 Results
08 May 2025 //
GLOBENEWSWIRE
Aptose updates Tuspetinib-based triple drug therapy in AML trial
05 May 2025 //
GLOBENEWSWIRE
Aptose to Present at 2025 Bloom Burton Healthcare Conference
23 Apr 2025 //
GLOBENEWSWIRE
Aptose Announces Auditor Not Standing for Re-Appointment
23 Apr 2025 //
GLOBENEWSWIRE
Aptose Reports Year End 2024 Results and Corporate Highlights
28 Mar 2025 //
GLOBENEWSWIRE
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
17 Mar 2025 //
GLOBENEWSWIRE
Aptose Gets CSRC Nod To Escalate Dosing In Ph 1/2 Tuscany Trial
20 Feb 2025 //
GLOBENEWSWIRE
Aptose Announces Positive Decision by Nasdaq Hearings Panel
19 Dec 2024 //
GLOBENEWSWIRE
Aptose Publishes Preclinical on Tuspetinib’s Action in AML Cells
12 Dec 2024 //
GLOBENEWSWIRE
Aptose Data Supports Tuspetinib Triple Drug Therapy for AML
09 Dec 2024 //
GLOBENEWSWIRE
Aptose Signs CRADA with NCI for Tuspetinib in AML & MDS Trials
03 Dec 2024 //
GLOBENEWSWIRE
Aptose Biosciences Closes $8 Million Public Offering
25 Nov 2024 //
GLOBENEWSWIRE
Aptose Biosciences Announces $8M Public Offering Pricing
22 Nov 2024 //
GLOBENEWSWIRE
Aptose Reports Results for the Q3 2024
08 Nov 2024 //
GLOBENEWSWIRE
Aptose Receives $10M From Hanmi; Negotiating Future Collaboration
30 Aug 2024 //
GLOBENEWSWIRE
Aptose Reports Results for the Second Quarter 2024
08 Aug 2024 //
GLOBENEWSWIRE
Aptose Announces Receipt of Deficiency Notice from Nasdaq
19 Jul 2024 //
GLOBENEWSWIRE
Aptose Announces Results from Annual and Special Meeting of Shareholders
18 Jun 2024 //
GLOBENEWSWIRE
Aptose Presents Tuspetinib Findings At EHA 2024
14 Jun 2024 //
GLOBENEWSWIRE
Aptose Closes $4.43M At-The-Market Registered Direct Offering
03 Jun 2024 //
GLOBENEWSWIRE
Aptose Announces $4.43M Direct Offering Per Nasdaq Rules
31 May 2024 //
GLOBENEWSWIRE
Aptose Reports Results for the First Quarter 2024
14 May 2024 //
GLOBENEWSWIRE
Aptose To Report Q1 2024 Results, Clinical Strategy On May 14
06 May 2024 //
GLOBENEWSWIRE
Aptose Reports Results for the Fourth Quarter and Full Year 2023
26 Mar 2024 //
GLOBENEWSWIRE
Aptose to Report Fourth Quarter & Year End 2023 Financial Results & Provid
18 Mar 2024 //
GLOBENEWSWIRE
Aptose to Report Fourth Quarter and Year End 2023 Financial Results
18 Mar 2024 //
GLOBENEWSWIRE
Aptose Announces Closing of $9.7 Million Public Offering
31 Jan 2024 //
GLOBENEWSWIRE
Aptose Announces Pricing of $8.4 Million Public Offering
26 Jan 2024 //
GLOBENEWSWIRE
Aptose Tuspetinib Data Featured in Oral Presentation
09 Dec 2023 //
GLOBENEWSWIRE
Aptose Appoints Fletcher Payne Chief Business Officer
30 Nov 2023 //
GLOBENEWSWIRE
Aptose Reports Results for the Third Quarter 2023
09 Nov 2023 //
GLOBENEWSWIRE
Aptose Tuspetinib Clinical Data Selected for Presentation at the 2023 ASH
02 Nov 2023 //
GLOBENEWSWIRE
Aptose Presents Highlights from Webcast Featuring Data on AML Drug Tuspetinib
30 Oct 2023 //
GLOBENEWSWIRE
Aptose to Report Third Quarter 2023 Financial Results
26 Oct 2023 //
GLOBENEWSWIRE
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib
23 Oct 2023 //
GLOBENEWSWIRE
Aptose Data to be Presented at ESH 6th International Conference
16 Oct 2023 //
GLOBENEWSWIRE
Aptose to Present at the Cantor Global Healthcare Conference
18 Sep 2023 //
GLOBENEWSWIRE
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
06 Sep 2023 //
GLOBENEWSWIRE
Aptose to Present at H.C. Wainwright 25th Annual Global Investment Conference
24 Aug 2023 //
GLOBENEWSWIRE
Aptose Reports Results for the Second Quarter 2023
10 Aug 2023 //
GLOBENEWSWIRE
Aptose to Report Second Quarter 2023 Financial Results
27 Jul 2023 //
GLOBENEWSWIRE
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
26 Jun 2023 //
GLOBENEWSWIRE
Aptose Presents Highlights from Clinical Update
10 Jun 2023 //
GLOBENEWSWIRE
Aptose Biosciences Provides Update on Reverse Stock Split
05 Jun 2023 //
GLOBENEWSWIRE
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
31 May 2023 //
GLOBENEWSWIRE
